Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04459221
Other study ID # 2020/CHU/05
Secondary ID 2020-002332-73
Status Completed
Phase Phase 4
First received
Last updated
Start date November 1, 2020
Est. completion date December 30, 2021

Study information

Verified date March 2022
Source Centre Hospitalier Universitaire de la Réunion
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Cervical cancer (CCU) is the fourth most common cancer in women worldwide. In Reunion island, CCU is the third leading cause of cancer in women (standardized incidence rate on the world population (TIS) in 2013 of 10.3 / 100,000) and is the eighth deadliest cancer with a rate standardized mortality of 4.8 / 100,000, almost three times higher than in mainland France where it was 1.7 / 100,000 in 2018. CCU results from infection with the human papillomavirus (HPV), which is the most common sexually transmitted viral infection. CCU prevention is mainly based on cervical smear screening and anti HPV vaccination (VHPV) which has demonstrated its effectiveness on the prevalence of HPV carriage, but also on incidence of condyloma or intermediate grade dysplasia. Since HPV is mainly transmitted sexually, it is important to vaccinate before the start of sex. In Reunion island, the HPV vaccination coverage rate is the lowest in France, estimated by Public Health France at 8.1% among girls aged 16 years in 2018, while the already low national average was established 23.7%. Thus, in view of the epidemiological situation in Reunion island (high incidence and mortality for the CCU, very low VHPV coverage rate), we thought it would be interesting to study the impact of a health promotion program sex and prevention of sexually transmitted infections (STIs) including papillomavirus-related pathologies, with a program to promote HPV vaccination among young students in middle school.


Recruitment information / eligibility

Status Completed
Enrollment 355
Est. completion date December 30, 2021
Est. primary completion date June 25, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 9 Years to 17 Years
Eligibility Inclusion Criteria: - schooled in one of the classes drawn at random in the 2 colleges selected for the study, - members or beneficiaries of a social security scheme, - having agreed to participate in the study and whose parents or holder (s) of parental authority have signed a free, informed and written consent. Exclusion Criteria: - under the age of 9, or over the age of 17 at inclusion, - with hypersensitivity to the active substances or to any of the excipients of the vaccine (Gardasil 9®), - with a permanent contraindication to vaccination. - having already initiated the HPV vaccination (complete or incomplete scheme). Students with an incomplete vaccination schedule will be referred to their attending physician to complete the missing dose (s). - pregnancy or breastfeeding (based on the declaration)

Study Design


Intervention

Drug:
Gardasil 9, 9-Valent Intramuscular Suspension
access to HPV vaccination near the college in a health bus

Locations

Country Name City State
France Centre Hospitalier Universitaire de la Réunion Saint-Pierre

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire de la Réunion

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change the vaccination rate in girls Number of girls having completed a complete vaccination schedule. Hypothesis: the intervention under study should increase the rate of vaccinated 9 month
Secondary increase the vaccination rate in all student number of student having completed a complete vaccination schedule 9 month
Secondary increase the vaccination rate in all student number of student having completed a incomplete vaccination schedule 9 month
See also
  Status Clinical Trial Phase
Completed NCT03584308 - Efficacy of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal Phase 2
Completed NCT05078554 - HPV and Male Homosexuality in General Practice?
Not yet recruiting NCT06416150 - Reducing Urban Cervical Cancer Disparities N/A
Completed NCT02114385 - A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020) Phase 3
Recruiting NCT05916911 - Evaluation Of The Efficacy Of The Combination Of GLIZIGEN® Oral Solution 1/Day And Vaginal Gel 1/Night For 2 Months In Patients With Cervical Intraepithelial Neoplasia Grade 1 (LSIL/CIN-1) Caused By High-Risk Human Papillomavirus (HPV-AR) Phase 4
Completed NCT01030562 - Immunogenicity of Off-Schedule Dosing of HPV Vaccine